Hormone Refractory Prostate Cancer Terminated Phase 3 Trials for Docetaxel (DB01248)
Also known as: Hormone Refractory Prostate Cancer Disease / Hormone-Refractory Prostate Cancer / Castration-resistant prostate cancer / Hormone refractory prostate cancer (disorder)
| Indication | Status | Phase |
|---|---|---|
| DBCOND0030609 (Hormone Refractory Prostate Cancer) | Terminated | 3 |
| clinicaltrials.gov Identifier | Title | Purpose | Drugs |
|---|---|---|---|
| NCT01083615 | A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC) | Treatment |